Literature DB >> 19707824

Identification of risk factors for an unfavorable laparoscopic cholecystectomy course after endoscopic retrograde cholangiography in the treatment of choledocholithiasis.

S C Donkervoort1, O van Ruler, L M Dijksman, A A van Geloven, E G Pierik.   

Abstract

BACKGROUND: Laparoscopic cholecystectomy (LC) after an endoscopic retrograde cholangiography (ERC) has higher rates for complications and conversion caused by unpredictable adhesions. The risk factors for an adverse outcome of LC after an ERC were analyzed.
METHODS: Variables from patients treated by LC after ERC for cholelithiasis in two clinics from 1996 to 2003 were retrospectively stored in a database. Complications and conversions were recorded.
RESULTS: A total of 140 patients underwent LC after ERC (83 from clinic A and 57 from clinic B), 31% (44/140) of whom were men. Peri- or postoperative complications occurred for 28 patients (20%). For 19 patients (14%), a conversion was necessary. Significant variables associated with complications and conversions were an elevated level of C-reactive protein (CRP) at the time of LC (odds ratio [OR], 10.2; 95% confidence interval [CI], 1.1-91, P = 0.037 for both) and severe adhesions during laparoscopy (OR, 3.6; 95% CI, 1.5-8.6; P = 0.003 and OR, 5.2; 95% CI, 1.9-14.4; P = 0.002, respectively). Male gender (OR, 2.8; 95% CI, 1.1-7.6; P = 0.037) and serum bilirubin level at the time of ERC (OR, 3.7; 95% CI, 1.24-11; P = 0.014) were associated with conversion only. Time after ERC (LC within 1 week vs. >1 week or < or = 2 weeks vs. 2-6 weeks vs. >6 weeks or < or = 6 weeks vs. >6 weeks) was not associated with complications or conversion. Multivariate regression analysis showed a pre-LC CRP exceeding 6 to be predictive of complications (OR, 10.5; 95% CI, 1.1-95; P = 0.040) and conversion (OR, 10.6; 95% CI, 1.1-99; P = 0.034).
CONCLUSION: Male gender, bilirubin levels during ERC, severe adhesions during LC, and pre-LC CRP levels were associated with an adverse outcome for an LC after endoscopic cholangiography. The time between LC and ERC failed to be a significant risk factor in this larger series.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19707824     DOI: 10.1007/s00464-009-0659-0

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


  22 in total

1.  Laparoscopic cholecystectomy for acute cholecystitis: can the need for conversion and the probability of complications be predicted? A prospective study.

Authors:  A Brodsky; I Matter; E Sabo; A Cohen; J Abrahamson; S Eldar
Journal:  Surg Endosc       Date:  2000-08       Impact factor: 4.584

2.  Preoperative endoscopic sphincterotomy and laparoscopic cholecystectomy for the management of cholecystocholedocholithiasis: 10-year experience.

Authors:  Leopoldo Sarli; Domenico R Iusco; Luigi Roncoroni
Journal:  World J Surg       Date:  2003-02       Impact factor: 3.352

3.  Endoscopic sphincterotomy prior to laparoscopic cholecystectomy for the treatment of cholelithiasis.

Authors:  K K Chang; L R Mo; M P Yau; R C Lin; J Y Kuo; C C Tsai
Journal:  Hepatogastroenterology       Date:  1996 Jan-Feb

4.  Symptomatic cholelithiasis: a different disease in men? Connecticut Laparoscopic Cholesystectomy Registry.

Authors:  J C Russell; S J Walsh; L Reed-Fourquet; A Mattie; J Lynch
Journal:  Ann Surg       Date:  1998-02       Impact factor: 12.969

5.  Outcomes analysis of laparoscopic cholecystectomy in the extremely elderly.

Authors:  L M Brunt; M A Quasebarth; D L Dunnegan; N J Soper
Journal:  Surg Endosc       Date:  2001-05-02       Impact factor: 4.584

6.  A risk score for conversion from laparoscopic to open cholecystectomy.

Authors:  N A Kama; M Kologlu; M Doganay; E Reis; M Atli; M Dolapci
Journal:  Am J Surg       Date:  2001-06       Impact factor: 2.565

7.  Cholangitis score: a scoring system to predict severe cholangitis in gallstone pancreatitis.

Authors:  Masatoshi Isogai; Akihiro Yamaguchi; Tohru Harada; Yuji Kaneoka; Masahiko Suzuki
Journal:  J Hepatobiliary Pancreat Surg       Date:  2002

8.  Wait-and-see policy or laparoscopic cholecystectomy after endoscopic sphincterotomy for bile-duct stones: a randomised trial.

Authors:  Djemila Boerma; Erik A J Rauws; Yolande C A Keulemans; Ignace M C Janssen; Clemens J M Bolwerk; Ron Timmer; Egge J Boerma; Huug Obertop; Kees Huibregtse; Dirk J Gouma
Journal:  Lancet       Date:  2002-09-07       Impact factor: 79.321

9.  Laparoscopic cholecystectomy. Cause of conversions in 1,300 patients and analysis of risk factors.

Authors:  P Schrenk; R Woisetschläger; W U Wayand
Journal:  Surg Endosc       Date:  1995-01       Impact factor: 4.584

10.  Biliary symptoms and complications more than 8 years after endoscopic sphincterotomy for choledocholithiasis.

Authors:  F Prat; N A Malak; G Pelletier; C Buffet; J Fritsch; A D Choury; C Altman; C Liguory; J P Etienne
Journal:  Gastroenterology       Date:  1996-03       Impact factor: 22.682

View more
  13 in total

1.  Outcome of laparoscopic cholecystectomy conversion: is the surgeon's selection needed?

Authors:  Sandra C Donkervoort; Lea M Dijksman; Lincey C F de Nes; Pieter G Versluis; Joris Derksen; Michael F Gerhards
Journal:  Surg Endosc       Date:  2012-03-08       Impact factor: 4.584

2.  Does endoscopic retrograde cholangiopancreatography have a negative effect on laparoscopic cholecystectomy?

Authors:  Murat Çakır; Tevfik Küçükkartallar; Ahmet Tekin; Mehmet Aykut Yıldırım; Adil Kartal
Journal:  Ulus Cerrahi Derg       Date:  2015-04-09

Review 3.  One-stage laproendoscopic procedure versus two-stage procedure in the management for gallstone disease and biliary duct calculi: a systemic review and meta-analysis.

Authors:  Pankaj Prasson; Xueli Bai; Qi Zhang; Tingbo Liang
Journal:  Surg Endosc       Date:  2015-12-30       Impact factor: 4.584

4.  Impact of Jaundice on Outcomes Following Emergency Laparoscopic Cholecystectomy in Patients with Choledocholithiasis.

Authors:  Benjamin R Poh; Paul A Cashin; Daniel G Croagh
Journal:  World J Surg       Date:  2018-10       Impact factor: 3.352

5.  High rate of common bile duct stones and postoperative abscess following percutaneous cholecystostomy.

Authors:  R Furtado; P Le Page; G Dunn; G L Falk
Journal:  Ann R Coll Surg Engl       Date:  2016-01-07       Impact factor: 1.891

6.  Laparoscopic cholecystectomy is more difficult after a previous endoscopic retrograde cholangiography.

Authors:  Jan Siert Kayitsinga Reinders; Dirk Joan Gouma; Joos Heisterkamp; Ellen Tromp; Bert van Ramshorst; Djamila Boerma
Journal:  HPB (Oxford)       Date:  2012-10-04       Impact factor: 3.647

7.  Single-stage laparoscopic common bile duct exploration and cholecystectomy versus two-stage endoscopic stone extraction followed by laparoscopic cholecystectomy for patients with gallbladder stones with common bile duct stones: systematic review and meta-analysis of randomized trials with trial sequential analysis.

Authors:  Anand Narayan Singh; Ragini Kilambi
Journal:  Surg Endosc       Date:  2018-03-30       Impact factor: 4.584

8.  Single-stage laparoscopic common bile duct exploration and cholecystectomy versus two-stage endoscopic stone extraction followed by laparoscopic cholecystectomy for patients with concomitant gallbladder stones and common bile duct stones: a randomized controlled trial.

Authors:  Virinder Kumar Bansal; Mahesh C Misra; Karthik Rajan; Ragini Kilambi; Subodh Kumar; Asuri Krishna; Atin Kumar; Chandrakant S Pandav; Rajeshwari Subramaniam; M K Arora; Pramod Kumar Garg
Journal:  Surg Endosc       Date:  2013-10-26       Impact factor: 4.584

9.  Surgeon's volume is not associated with complication outcome after laparoscopic cholecystectomy.

Authors:  Sandra C Donkervoort; Lea M Dijksman; Pieter G Versluis; Emile A Clous; Anco C Vahl
Journal:  Dig Dis Sci       Date:  2013-10-01       Impact factor: 3.199

10.  Post-endoscopic retrograde cholangiography laparoscopic cholecystectomy: challenging but safe.

Authors:  Kulbir Mann; Ajay P Belgaumkar; Sukhpal Singh
Journal:  JSLS       Date:  2013 Jul-Sep       Impact factor: 2.172

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.